Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Lexeo Therapeutics reported Q2 2026 financials and operational updates, highlighting the initiation of the pivotal SUNRISE-FA 2 trial for LX2006 targeting Friedreich ataxia cardiomyopathy with topline data expected in H2 2027. The company received FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy, supporting expedited developmen…